Company: REVB
Filing Date: 2025-03-06
Form Type: 10-K
Source: 0000950170-25-034584
Chunk: 213

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-03-06
Form: 10-K
Item: Item 1B
Chunk 213
---
 provided by financing activities

    12,847,764

    14,025,008

    Net (decrease) increase in cash and cash equivalents

    (5,492,683
    )

    6,738,722

    Cash and cash equivalents at beginning of period

    11,991,701

    5,252,979

    Cash and cash equivalents at end of period
     
    $
    6,499,018

    $
    11,991,701

    Supplemental disclosure of non-cash investing and financing activities:

    Fair Value of Class G Common Stock Warrants
     
    $
    2,066,429

    $
    —

    Fair Value of Class F Common Stock Warrants
     
    $
    4,104,680

    $
    —

    Fair Value of Class E Common Stock Warrants in connection with the Class D Warrant Inducement
     
    $
    4,887,683

    $
    —

    Incremental fair value of the Class D Common Stock Warrants in connection with the Class D Warrant Inducement
     
    $
    939,679

    $
    —

    Equity issuance costs in connection with the Class D Warrant Inducement included in accounts payable
     
    $
    25,968

    $
    —

    Fair Value of Class D Common Stock Warrants in connection with the February 2024 Public Offering
     
    $
    6,269,684

    $
    —

    Fair Value of Class C Common Stock Warrants in connection with the February 2023 Public Offering
     
    $
    —

    $
    13,996,500

    Alternative cashless exercise of Class C Common Stock Warrants
     
    $
    57,589

    $
    5,526,287

    Deferred offering costs included in accounts payable and accrued expenses
     
    $
    —

    $
    66,033

See accompanying notes to the consolidated financial statements.

 F-7

REVELATION BIOSCIENCES, INC. 

Notes to the Consolidated Financial Statements

1. Organization and Basis of PresentationRevelation Biosciences, Inc. (collectively with its wholly-owned subsidiaries, referred to as “we,” us,” “our,” “Revelation,” or the “Company”) is a clinical-stage life science company that is focused on rebal